Ticker LaunchIPO · XGN
Exagen Inc.
Formerly EXAGEN DIAGNOSTICS INC
Exagen Inc. (XGN) priced its initial public offering on Sep 20, 2019 at $14.00 per share, within its $14.00–$16.00 range, raising $50.4M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $160.9M. Latham & Watkins advised the company and Cooley advised the underwriters.
Exagen Inc. is a diagnostics company focused on chronic autoimmune diseases, selling testing products under the AVISE brand. Several are based on its proprietary CB-CAPs technology, which assesses complement system activation, and are aimed at helping rheumatologists diagnose and monitor lupus and rheumatoid arthritis.
- Status
- IPO
- Ticker
- XGN
- Exchange
- Nasdaq Global Market
- Priced
- Sep 20, 2019
- IPO price
- $14.00
- Price range
- $14.00–$16.00
- Raised
- $50.4M
- Market cap at IPO price
- $160.9M
- First filed
- Sep 19, 2014
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Cooley
- Sector
- Healthcare
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 19, 2014
- Latest amendment Sep 9, 2019
- Final prospectus (424B4) Sep 20, 2019
- All filings on EDGAR CIK 1274737
Other Healthcare IPOs in 2019
- Centogene N.V.CNTG · Nov 8, 2019 · $56M
- Aesthetic Medical International Holdings Group LtdAIH · Oct 25, 2019 · $30M
- Progyny, Inc.PGNY · Oct 25, 2019 · $130M
- Envista Holdings CorpNVST · Sep 19, 2019 · $588.9M
- SmileDirectClub, Inc.SDC · Sep 13, 2019 · $1.35B
- InMode Ltd.INMD · Aug 8, 2019 · $70M